The history of dopamine and levodopa in the treatment of Parkinson's disease
Identifieur interne : 000C45 ( Main/Exploration ); précédent : 000C44; suivant : 000C46The history of dopamine and levodopa in the treatment of Parkinson's disease
Auteurs : Stanley Fahn [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
English descriptors
Abstract
The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder. This review describes these events and the persons who carried out these accomplishments. Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22028
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The history of dopamine and levodopa in the treatment of Parkinson's disease</title><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6C17BB4B527CC2DC350FB59E0CD1784A99B54001</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22028</idno><idno type="url">https://api.istex.fr/document/6C17BB4B527CC2DC350FB59E0CD1784A99B54001/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000F69</idno><idno type="wicri:Area/Main/Curation">000D87</idno><idno type="wicri:Area/Main/Exploration">000C45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The history of dopamine and levodopa in the treatment of Parkinson's disease</title><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Columbia University, New York</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S497">S497</biblScope><biblScope unit="page" to="S508">S508</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6C17BB4B527CC2DC350FB59E0CD1784A99B54001</idno><idno type="DOI">10.1002/mds.22028</idno><idno type="ArticleID">MDS22028</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>history</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder. This review describes these events and the persons who carried out these accomplishments. Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region><settlement><li>New York</li></settlement><orgName><li>Université Columbia</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6C17BB4B527CC2DC350FB59E0CD1784A99B54001
|texte= The history of dopamine and levodopa in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |